Melissa Raven (@psychepi) profile picture

Psychiatric epidemiologist policy analyst Critic of dodgy claims/bandwagons/propaganda/conflicts of interest. JSBachtragic Klavierschülerin Ambulophile Aviphile

Joined September 2011
Photo by Melissa Raven (@psychepi)Photo by Melissa Raven (@psychepi)Photo by Melissa Raven (@psychepi)Photo by Melissa Raven (@psychepi)
Have you ever wondered why your doctor doesn't listen to your report of an adverse drug effect? Does your doctor want you to suffer? No, your doctor just wants you to shut up & take your medicine.
Prof @JamesStein18 Is Sensitive to Medicine - Just Like Everyone Else: But most people cannot be more sensitive than most people jamesstein18.substack.com/p/…
1
6
18
458
Melissa Raven retweeted
I credit Dr. Lesaca for addressing the issue of antidepressants & pregnancy in this article. He is correct that none of the antidepressants are "proven safe" in pregnancy. Some concerns I have are: #1. There is no mention of the increased risk of postpartum hemorrhage (PPH) with SSRIs. PPH is a leading cause of maternal morbidity & mortality. This risk is on the SSRI labels and must be reviewed with patients. #2. There is no mention of the long-term effects on the developing fetal brain. We now have thirteen (13) consecutive MRI studies showing evidence of altered brain development with SSRI exposure. And we also have numerous studies showing differences in language and motor skills, school performance, mental health, and neurobehavioral disorders. #3. There is no mention of the risks of pregnancy loss and low birth weight, associations which have been demonstrated in many animal and human studies. #4. The article suggests that "untreated maternal illness" increases pregnancy complications. It is true that some studies show that depression is associated with some obstetrical complications. But the use of the term "untreated maternal illness" suggests that treating women with antidepressants has been proven to improve pregnancy outcomes. This is not the case. In fact, the majority of studies in this area show that the antidepressant-treated women have worse (not better) obstetrical outcomes (eg more preterm birth, low birth weight, & preeclampsia.) I credit him for recognizing that antidepressants cannot be said to be "proven safe" in pregnancy. But proper patient counseling requires us to go beyond this and to fully explain the risks (and benefits and alternatives) to patients. kevinmd.com/2026/11/which-an…
3
24
1
34
1,430
I've been invited to participate in this year's Maudsley Debate, supporting the notion: 'This House Believes that Biological Psychiatry has Failed to Deliver Significant Benefit for Patients'. - Attendance is free - reserve your place below 👇 eventbrite.co.uk/e/65th-maud…
10
34
4
102
7,807
Fantastic to see awareness of psychiatric drug withdrawal and safe deprescribing to Greece. Greek citizens are very lucky to have @GKasioumi as a fierce champion of this work. Again, how much of an indictment it is of the status quo that patients harmed by drugs have to take on the effort to educate clinicians about the harm they have done.
On November 7, we held the 1st SafeMeds Hellas Forum on Antidepressant Withdrawal in Greece, bringing together distinguished scientists, healthcare professionals, and people with lived experience. 📊 More than 6,500 page views and 365 registrations! My deepest gratitude to @markhoro for his invaluable scientific contribution, trust, and generous support of this initiative. Sincere thanks to all our speakers, moderators, and participants for contributing to this important dialogue on antidepressant withdrawal, patient safety, and safer clinical practices. #SafeMedsHellas #AntidepressantWithdrawal #MarkHorowitz #Deprescribing #PatientSafety
1
18
1
49
1,392
Piece on diagnosis acting as an 'identity intervention,’ influencing 'the self-concept, expectations, and life story of a person with mental health issues in a potentially harmful way that goes beyond the descriptive function of the diagnostic label'. journals.plos.org/mentalheal…
12
30
4
97
5,229
Thank you Daniel. This is why I wrote Chemically Imbalanced, because this myth has fundamentally shaped people's views and decisions about antidepressants. The pharmaceutical industry knew it would and the psychiatric profession played along. People need to know the truth.
The Chemical Imbalance Myth: What Jack Goulder Gets Wrong I've read the recent Substack article by Jack Goulder entitled Merchants of Psychiatric Doubt and the subsequent exchanges with Dr Horowitz. First of all, I think it was poor judgment of Goulder to misquote Horowitz and Moncrieff, particularly when that quotation was central to his accusation that they had misrepresented their research. More fundamentally, though I think his dismissal of Horowitz's argument as "semantic somersaults" overlooks an important historical distinction. Contrary to the impression given in the article, the chemical imbalance theory was not simply a marketing narrative seized upon by drug companies. It was actively promoted and legitimised by influential figures within institutional medicine, particularly psychiatry. Until relatively recently, the NHS reproduced versions of this explanation on its websites, and as recently as 2025, Rebecca Brendel, a former president of the American Psychiatric Association, was publicly linking low serotonin with depression in the Washington Post. Psychiatry itself helped establish the credibility of this narrative, and the profession's role in promoting it deserves serious historical scrutiny. This matters because the chemical imbalance theory was not merely an abstract scientific hypothesis. It fundamentally shaped how depression was understood by the public, how SSRIs were presented to patients, and potentially how people made decisions about treatment. Millions of people were given the impression, by psychiatrists, GPs and medical journalism, that SSRIs corrected an underlying chemical deficiency. That is a very different proposition from telling patients that these drugs alter brain chemistry in ways we do not fully understand, that their average benefits over placebo are relatively modest, and that they carry risks. The chemical imbalance narrative also had important implications for long term prescribing. If patients believed they had an underlying serotonin deficiency, it was entirely reasonable for them to conclude that they might need medication indefinitely, just as someone with diabetes might require insulin. Whether and to what extent that belief contributed to long term prescribing deserves investigation, but it is hardly a trivial question. In other words, the theory that depression results from low serotonin played an important role in legitimising the widespread use of SSRIs, including their long term use. We now know that this explanation was not supported by the evidence. It is therefore entirely reasonable to say that research challenging the serotonin hypothesis also calls into question one of the principal historical rationales offered for prescribing these drugs. It is true that this is not the same as claiming that SSRIs have been demonstrated to be ineffective. Whether a drug produces a clinically meaningful benefit is a separate empirical question from whether it corrects the biological abnormality it was purportedly prescribed to treat. The is a substantive difference not a semantic one. It also raises important questions about informed consent. Patients are entitled to accurate explanations of why a treatment is being recommended, not simply evidence that it may produce some benefit. What I find particularly striking about the article is that Goulder devotes considerable attention to the philosophical commitments of psychiatry's critics, while giving comparatively little scrutiny to the professional and institutional commitments that helped sustain the chemical imbalance narrative for decades. If his concern is how prior beliefs and institutional interests shape the interpretation and communication of scientific evidence, surely that scrutiny should apply equally to mainstream psychiatry. One can reasonably argue that the serotonin hypothesis has no direct bearing on the evidence from antidepressant efficacy trials. But it does not follow that discrediting the hypothesis has no bearing on the historical justification for prescribing these medications, or on the decisions patients made after being told they suffered from a chemical imbalance. To characterise that distinction as "semantic" is, I think, to fundamentally miss the point of why setting the record straight about the chemical imbalance story matters so much.
1
17
78
2,290
Melissa Raven retweeted
In this NEW Study, SSRI-exposed newborns had a nearly FIVE-fold increased risk of an Apgar score < 7. The authors write: "A possible explanation is the direct effect of SSRIs on the development of the fetal brain."
NEW Study: -SSRI users were more likely to have neonates with head circumference < 35 cm & had nearly FIVE-fold higher odds of 5 min Apgar score < 7. -SSRI users also had ⬆️ rates of postpartum hemorrhage & early-term birth. -Rates of prenatal SSRI use increased roughly NINE-fold in Sweden from 2005 to 2015. tandfonline.com/doi/full/10.…
4
16
44
1,163
Thank you, Mark, for correcting the record and making it clear that we did NOT misrepresent our research, as accused. I have requested that the Journal that published this paper issues a correction too.
Jack has not permitted comments to be put on his blog so I’ll post this here. Many of the points in his blog are false. He has latterly corrected the quotation from our press release after I emailed him (although he does not disclose this was the reason for his correction). As he now acknowledges, we did not say what he had quoted us as saying and he has now corrected the quotation to say “this research calls into question reasonsfor the use of antidepressants.” Of course our paper calls into question the main rationale given to patients for prescribing these drugs – of course it calls the ‘reasons’ into question. He and others may wish to argue that the drugs are prescribed because they are effective (discussed at length elsewhere) but the rationale presented to many patients was (and is) false. Naturally, if it were found that Hashimoto’s disease was not caused by low thyroid hormones it would throw into question the rationale for prescribing thyroid hormones. It would throw into relief questions about long term harms and benefits of such a treatment that would not be raised if the treatment was acting in the self-evidently sensible manner of correcting a hormonal deficit. His central accusation – and the central point of his published article – is that we misleadingly presented our review regarding the aetiology of depression as showing that antidepressants are ineffective. We did not such thing. Jack could find no such quote in our press release so he fudged it. (I believe this is the polite euphemism). Of course such a finding about aetiology invites reflection on the efficacy of the drugs and so naturally we discussed this in the Conversation piece - our comments in this piece are all supported by evidence. His statement about the Nordic Cochrane is also false. Nordic Cochrane moved from Righospitalet in Copenhagen to the University of Southern Denmark in Odense where it merged with the Centre for Evidence-Based Medicine and was renamed to Cochrane Denmark. It still functions today and houses the Cochrane Bias Methods Group which advises Cochrane : www2.cochrane.dk/ He is performing quite some somersaults, slinging mud from unrelated comments made by Peter Breggin, and Peter Gotzsche, to avoid reading an article published in the BMJ Open. An article I would still encourage him and other to read so that they become aware of the substantive criticisms of Cipriani’s meta-analysis rather than assuming the solidity of claims made about antidepressant efficacy: bmjopen.bmj.com/content/9/6/… I expect that after correcting his recent blog he will also correct his original blog on Awais’ website (where he falsely says: “a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) and his academic paper were he makes the same false claim (“a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) as he has now acknowledged that these claims are false. I would like to be notified when these corrections are made.
1
7
51
2,046
Melissa Raven retweeted
Replying to @dsowens17
I do struggle to understand the tenacity with which psychiatry clings to antidepressants. They just…aren’t very effective for most people. The risk/benefit ratio is all risk and no benefit in most cases. Time to pack up and move on surely? Instead, having lost the argument on the evidence, Goulder and co misrepresent and take swipes at the perceived politics of researchers they disagree with. It’s very frustrating.
8
8
1
55
7,737
Melissa Raven retweeted
The Chemical Imbalance Myth: What Jack Goulder Gets Wrong I've read the recent Substack article by Jack Goulder entitled Merchants of Psychiatric Doubt and the subsequent exchanges with Dr Horowitz. First of all, I think it was poor judgment of Goulder to misquote Horowitz and Moncrieff, particularly when that quotation was central to his accusation that they had misrepresented their research. More fundamentally, though I think his dismissal of Horowitz's argument as "semantic somersaults" overlooks an important historical distinction. Contrary to the impression given in the article, the chemical imbalance theory was not simply a marketing narrative seized upon by drug companies. It was actively promoted and legitimised by influential figures within institutional medicine, particularly psychiatry. Until relatively recently, the NHS reproduced versions of this explanation on its websites, and as recently as 2025, Rebecca Brendel, a former president of the American Psychiatric Association, was publicly linking low serotonin with depression in the Washington Post. Psychiatry itself helped establish the credibility of this narrative, and the profession's role in promoting it deserves serious historical scrutiny. This matters because the chemical imbalance theory was not merely an abstract scientific hypothesis. It fundamentally shaped how depression was understood by the public, how SSRIs were presented to patients, and potentially how people made decisions about treatment. Millions of people were given the impression, by psychiatrists, GPs and medical journalism, that SSRIs corrected an underlying chemical deficiency. That is a very different proposition from telling patients that these drugs alter brain chemistry in ways we do not fully understand, that their average benefits over placebo are relatively modest, and that they carry risks. The chemical imbalance narrative also had important implications for long term prescribing. If patients believed they had an underlying serotonin deficiency, it was entirely reasonable for them to conclude that they might need medication indefinitely, just as someone with diabetes might require insulin. Whether and to what extent that belief contributed to long term prescribing deserves investigation, but it is hardly a trivial question. In other words, the theory that depression results from low serotonin played an important role in legitimising the widespread use of SSRIs, including their long term use. We now know that this explanation was not supported by the evidence. It is therefore entirely reasonable to say that research challenging the serotonin hypothesis also calls into question one of the principal historical rationales offered for prescribing these drugs. It is true that this is not the same as claiming that SSRIs have been demonstrated to be ineffective. Whether a drug produces a clinically meaningful benefit is a separate empirical question from whether it corrects the biological abnormality it was purportedly prescribed to treat. The is a substantive difference not a semantic one. It also raises important questions about informed consent. Patients are entitled to accurate explanations of why a treatment is being recommended, not simply evidence that it may produce some benefit. What I find particularly striking about the article is that Goulder devotes considerable attention to the philosophical commitments of psychiatry's critics, while giving comparatively little scrutiny to the professional and institutional commitments that helped sustain the chemical imbalance narrative for decades. If his concern is how prior beliefs and institutional interests shape the interpretation and communication of scientific evidence, surely that scrutiny should apply equally to mainstream psychiatry. One can reasonably argue that the serotonin hypothesis has no direct bearing on the evidence from antidepressant efficacy trials. But it does not follow that discrediting the hypothesis has no bearing on the historical justification for prescribing these medications, or on the decisions patients made after being told they suffered from a chemical imbalance. To characterise that distinction as "semantic" is, I think, to fundamentally miss the point of why setting the record straight about the chemical imbalance story matters so much.
5
22
3
59
4,904
Melissa Raven retweeted
Well said @dsowens17: "In other words, the theory that depression results from low serotonin played an important role in legitimising the widespread use of SSRIs, including their long term use. We now know that this explanation was not supported by the evidence. It is therefore entirely reasonable to say that research challenging the serotonin hypothesis also calls into question one of the principal historical rationales offered for prescribing these drugs."
The Chemical Imbalance Myth: What Jack Goulder Gets Wrong I've read the recent Substack article by Jack Goulder entitled Merchants of Psychiatric Doubt and the subsequent exchanges with Dr Horowitz. First of all, I think it was poor judgment of Goulder to misquote Horowitz and Moncrieff, particularly when that quotation was central to his accusation that they had misrepresented their research. More fundamentally, though I think his dismissal of Horowitz's argument as "semantic somersaults" overlooks an important historical distinction. Contrary to the impression given in the article, the chemical imbalance theory was not simply a marketing narrative seized upon by drug companies. It was actively promoted and legitimised by influential figures within institutional medicine, particularly psychiatry. Until relatively recently, the NHS reproduced versions of this explanation on its websites, and as recently as 2025, Rebecca Brendel, a former president of the American Psychiatric Association, was publicly linking low serotonin with depression in the Washington Post. Psychiatry itself helped establish the credibility of this narrative, and the profession's role in promoting it deserves serious historical scrutiny. This matters because the chemical imbalance theory was not merely an abstract scientific hypothesis. It fundamentally shaped how depression was understood by the public, how SSRIs were presented to patients, and potentially how people made decisions about treatment. Millions of people were given the impression, by psychiatrists, GPs and medical journalism, that SSRIs corrected an underlying chemical deficiency. That is a very different proposition from telling patients that these drugs alter brain chemistry in ways we do not fully understand, that their average benefits over placebo are relatively modest, and that they carry risks. The chemical imbalance narrative also had important implications for long term prescribing. If patients believed they had an underlying serotonin deficiency, it was entirely reasonable for them to conclude that they might need medication indefinitely, just as someone with diabetes might require insulin. Whether and to what extent that belief contributed to long term prescribing deserves investigation, but it is hardly a trivial question. In other words, the theory that depression results from low serotonin played an important role in legitimising the widespread use of SSRIs, including their long term use. We now know that this explanation was not supported by the evidence. It is therefore entirely reasonable to say that research challenging the serotonin hypothesis also calls into question one of the principal historical rationales offered for prescribing these drugs. It is true that this is not the same as claiming that SSRIs have been demonstrated to be ineffective. Whether a drug produces a clinically meaningful benefit is a separate empirical question from whether it corrects the biological abnormality it was purportedly prescribed to treat. The is a substantive difference not a semantic one. It also raises important questions about informed consent. Patients are entitled to accurate explanations of why a treatment is being recommended, not simply evidence that it may produce some benefit. What I find particularly striking about the article is that Goulder devotes considerable attention to the philosophical commitments of psychiatry's critics, while giving comparatively little scrutiny to the professional and institutional commitments that helped sustain the chemical imbalance narrative for decades. If his concern is how prior beliefs and institutional interests shape the interpretation and communication of scientific evidence, surely that scrutiny should apply equally to mainstream psychiatry. One can reasonably argue that the serotonin hypothesis has no direct bearing on the evidence from antidepressant efficacy trials. But it does not follow that discrediting the hypothesis has no bearing on the historical justification for prescribing these medications, or on the decisions patients made after being told they suffered from a chemical imbalance. To characterise that distinction as "semantic" is, I think, to fundamentally miss the point of why setting the record straight about the chemical imbalance story matters so much.
2
14
426
Jack has not permitted comments to be put on his blog so I’ll post this here. Many of the points in his blog are false. He has latterly corrected the quotation from our press release after I emailed him (although he does not disclose this was the reason for his correction). As he now acknowledges, we did not say what he had quoted us as saying and he has now corrected the quotation to say “this research calls into question reasonsfor the use of antidepressants.” Of course our paper calls into question the main rationale given to patients for prescribing these drugs – of course it calls the ‘reasons’ into question. He and others may wish to argue that the drugs are prescribed because they are effective (discussed at length elsewhere) but the rationale presented to many patients was (and is) false. Naturally, if it were found that Hashimoto’s disease was not caused by low thyroid hormones it would throw into question the rationale for prescribing thyroid hormones. It would throw into relief questions about long term harms and benefits of such a treatment that would not be raised if the treatment was acting in the self-evidently sensible manner of correcting a hormonal deficit. His central accusation – and the central point of his published article – is that we misleadingly presented our review regarding the aetiology of depression as showing that antidepressants are ineffective. We did not such thing. Jack could find no such quote in our press release so he fudged it. (I believe this is the polite euphemism). Of course such a finding about aetiology invites reflection on the efficacy of the drugs and so naturally we discussed this in the Conversation piece - our comments in this piece are all supported by evidence. His statement about the Nordic Cochrane is also false. Nordic Cochrane moved from Righospitalet in Copenhagen to the University of Southern Denmark in Odense where it merged with the Centre for Evidence-Based Medicine and was renamed to Cochrane Denmark. It still functions today and houses the Cochrane Bias Methods Group which advises Cochrane : www2.cochrane.dk/ He is performing quite some somersaults, slinging mud from unrelated comments made by Peter Breggin, and Peter Gotzsche, to avoid reading an article published in the BMJ Open. An article I would still encourage him and other to read so that they become aware of the substantive criticisms of Cipriani’s meta-analysis rather than assuming the solidity of claims made about antidepressant efficacy: bmjopen.bmj.com/content/9/6/… I expect that after correcting his recent blog he will also correct his original blog on Awais’ website (where he falsely says: “a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) and his academic paper were he makes the same false claim (“a press release written by Moncrieff and co-author Mark Horowitz explicitly linked the umbrella review to a lack of efficacy in antidepressants”) as he has now acknowledged that these claims are false. I would like to be notified when these corrections are made.
Replying to @markhoro
Thanks Mark, just posting my reply here. jocgoulder.substack.com/p/my…
4
20
2
49
4,397
Melissa Raven retweeted
NEW Study: -SSRI users were more likely to have neonates with head circumference < 35 cm & had nearly FIVE-fold higher odds of 5 min Apgar score < 7. -SSRI users also had ⬆️ rates of postpartum hemorrhage & early-term birth. -Rates of prenatal SSRI use increased roughly NINE-fold in Sweden from 2005 to 2015. tandfonline.com/doi/full/10.…
1
28
4
48
5,285
Melissa Raven retweeted
Can universal help for teens about mental health make them more depressed? A trial of 12,166 students in 153 English schools randomized them to: • YAM, a 5-session program led by trained facilitators • A 6-session teacher-led mental health literacy program (the Guide) • Usual practice YAM did not improve depressive symptoms. The Guide program increased help-seeking and knowledge. But at 9 to 12 months, depressive symptoms were worse in both programs than with usual practice (SMD 0.08 and 0.09). Effects are small, but consider rolling this out universally to millions of kids. From the authors: "these kinds of programmes may encourage rumination and self-labelling in such a way that it increases emotional distress." Ref: 10.1192/bjp.2026.10667
4
24
4
64
2,867
Thank you for setting the record straight. We did not, as accused, misrepresent the serotonin paper as demonstrating that antidepressants are not effective, although this is something I have explored in other research. 1/2
I've responded briefly to Jack's blog here: mhorowitz.substack.com/p/une… The two major problems with Jack Goulder’s blog (and the paper on which it is based) is, one, that Jack is working from the unquestioning (and largely unexamined) assumption that antidepressants work and anyone who suggests otherwise must have mischievous motivation. And two, he has misrepresented what we have said about our umbrella review. Jack said to me tellingly in an email: “I should be clear that my academic background is in history and social science, not epidemiology or pharmacology. I’m not sure I’m qualified to give a detailed analysis of the subtleties of this quite vast literature!” So without engaging with the debate about efficacy in any meaningful way he has embarked on what sounds like a year-long project on the premise that ‘the drugs work because senior people in my field agree they do’ and that he saw a young woman (with a different condition to the literature he is commenting on) improve with antidepressants ‘after a few months, and with the help of therapy too.’ This is not how science works. I sent him a very clear explanation of the issues with antidepressant efficacy written by a Cochrane group in Denmark – who I’m sure have never read Szasz! – published in the BMJ Open but he seems not to have read this: bmjopen.bmj.com/content/9/6/… To just briefly re-state the issues with the Cipriani review on antidepressants (which provides the basis of Jack and other’s unshakeable belief in the efficacy of these drugs): presenting response rates inflates the small absolute differences between antidepressant and placebo.1 This difference is 2 points on a 52 point depression scale.2 This lies below any analysis of what constitutes a clinically important difference (rather than just a statistically significant difference).3,4 See figure above to illustrate some of these elements. These studies only examine effects at 8 weeks, whilst people take these drugs for years.5 Even the small effects at 8 weeks are likely to wear off due to tolerance – the corollary of any drug that causes withdrawal.6 There are also unblinding effects – people who know they are on the drugs have raised expectations which improve mood and these expectations inflate the apparent effects of antidepressants in placebo-controlled trials.7 For example, in an analysis of the TADS study treatment guess had a substantial effect on outcome, while actual treatment group (antidepressant or placebo) did not.7 The Stone et al meta-analysis did not refute the role of unblinding as Jack suggests, it merely notes that the trials it included did not test the integrity of the double blind design (Stone writes “We cannot fully exclude the possibility that the effects of the drugs are accounted for by functional unblinding”). 8 There is also massive publication bias.9 The studies which find 15% of people benefit at an 8 week time point suffer from all the same limitations as above.8 And if there is a small pharmacological effect in the short term from this class of medication it leaves the question of the utility – or the ethics – of giving people drugs that numb their emotions when they are distressed,10 especially with the risk that for a portion of them this numbing does not wear off when the drugs are stopped.11,12 Jack’s piece ignores almost all of these issues. A central part of this argument is that Joanna and I put out a press release arguing that our paper had demonstrated antidepressants are ineffective. Notably he does not quote the lines from the press release in his blog or the paper – remarkable when this is a key part of his argument. Of course the reason he does not quote this is because his assertion is false. We don’t anywhere say in our draft press release that we have demonstrated in our umbrella review of the role of serotonin in depression that we have demonstrated that antidepressants are not effective. The closest we come is when we say: “Therefore, this research calls into question reasons for the use of antidepressants.” The research does indeed undermine a common reason for the prescription of antidepressants. I think what is most unsettling about this piece is that Jack has inverted the work of Naomi Oreskes. Her work and her book Merchants of Doubt sets out the playbook taken by large industries to undermine critics of their hegemony. When big tobacco was being criticised for causing lung cancer by researchers, it funded researchers who sewed doubt in this hypothesis by pointing to asbestos, stress, etc, anything other than tobacco which might cause lung cancer. The same playbook was used by fossil fuel companies: as climate scientists started pointing the finger at this industry for driving climate change, scientists associated with industry put out arguments sewing doubt: temperatures natural vary, humans couldn’t be doing it, etc. This is the identical playbook adopted by the pharmaceutical industry and its supporters when it comes to obscuring the harm of their products. Antidepressant withdrawal isn’t caused by stopping antidepressants, they say, it is caused by patient’s expectations of worsening (nocebo effects), their mental health condition returning, other diseases that co-incidentally occur at the same point (functional neurological disorder) and short-term withdrawal studies show that there is no real issue, etc.13,14 There is an absurdity to painting academics, many of whom are paid by one of the largest industries in the world as representing unimpeachably pure science and Joanna and a bunch of her academic colleagues (including me) as the ‘merchants of doubt’. Of course some of the scientists who defend the efficacy or minimise the harms of antidepressants are not paid by industry, but other interests, such as professional status, are also at play. I would strongly encourage Jack and anyone reading his essay to go and read criticisms of antidepressant efficacy before jumping to conclusions that anyone putting forward a criticism of the current consensus must be mischieviously motivated. The current (and poorly examined) consensus on the relative safety and effectiveness of antidepressants in the long-term has led to an avalanche of harm that can be seen spilling out onto social media, newspaper articles, government inquiries, parliamentary groups and, increasingly, concrete NHS projects and directives. Rather than expending further energy trying to shoot (and silence) some of the messengers it would be better for patients if psychiatrists examined the reality of what is occurring to patients and stopped deriving false reassurance from short term studies centrally concerned with commercial objectives. References available at: mhorowitz.substack.com/p/une…
3
18
79
4,736
Melissa Raven retweeted
Let’s push the @FDA to follow the UK’s MHRA and require specific warnings about Post-SSRI Sexual Dysfunction (PSSD). And while we’re at it, let’s strengthen the suicide risk warnings to include ALL ages, not just those 24 and younger. We’ve been fighting to remove that age cutoff since 2006. Drug-induced suicidal thoughts and behaviors don’t magically stop when someone turns 25. The FDA’s failure to specifically warn about PSSD raises a much bigger question: How can patients give informed consent when important risks aren’t disclosed? It’s exactly why I created the petition at antidepressantinjury.com. We need to make the voices of those harmed impossible to ignore. Patients deserve to know the risks BEFORE taking these drugs, regardless of their age or where they live. Informed consent isn’t optional. It’s a patient’s right. Another great article by @AKECassels and @brownstoneinst
Shockingly, the US FDA has yet to require a specific warning about persistent post-SSRI sexual dysfunction (PSSD), revealing how much the US system has been captured by the drug companies it allegedly regulates. ~@AKECassels Why Weren’t We Warned? brownstone.org/articles/why-…
3
41
97
1,987
Melissa Raven retweeted
Reminder: "findings do not support the use of antipsychotic augmentation in patients with treatment-resistant depression." A 2025 study followed almost 40,000 patients with treatment-resistant depression given an antipsychotic and compared them with matched patients given another antidepressant. Antipsychotics did not reduce suicide outcomes, though suicide death showed a concerning signal (HR 1.22, 0.91–1.71). All-cause mortality was higher on antipsychotics (HR 1.21, 1.07–1.33). Ref: 10.1192/bjp.2024.283
Aripiprazole or bupropion for antidepressant augmentation? Similar in new trial of anxious #depression. Learn why bupropion causes less anxiety than often thought: psych-partners.com/aripipraz…
15
16
1
78
4,668
Melissa Raven retweeted
sign up to this event. AD4E are one of the most important organisations campaigning for better mental health for all by acknowledging the harms our current diagnostic models cause: eventbrite.co.uk/e/196864998…
5
7
869
Melissa Raven retweeted
Such great advice. 🦋 Coming from someone who once wondered if she would ever make it through grief, @drleewarrenmd words really resonated with me. The heartache of losing someone you love is real. And so is the possibility of healing. 🦋🦋
Most people think the five stages of grief are a map for losing someone you love. But they came from interviews with patients who had just found out they were dying. 
Stay with me to the end, and I'll show you what grief actually looks like in people who've lost someone, and the one thought you need to stop believing about your own grief. 
I'm a brain surgeon. I've had the hardest conversations a family can have, in hospital hallways and waiting rooms, and I've studied what grief does to the brain. Let's scrub in and get after it. 
In 1969, Dr. Elisabeth Kübler-Ross published On Death and Dying, based on interviews with more than 200 terminally ill patients. Denial, anger, bargaining, depression, acceptance. She was describing people facing their own death. The rest of us borrowed those stages for bereavement, and they turned into a checklist. When Yale researchers finally tested the stages in 233 people who had lost a loved one, the checklist didn't hold. Acceptance was the most common response from early on. And the strongest pain wasn't anger or depression. It was yearning, the ache of missing them and wanting them back. 
So here's what grief really looks like: you can accept that they're gone and still ache for them every day. Both at once. That's normal. The third commandment of self-brain surgery is: I must believe that most of my automatic thoughts are untrue. And "I'm grieving wrong" is one of those lying thoughts. Hit that follow button so you don't miss the next one, and send this to someone who thinks they're grieving wrong. When it shows up, examine the tissue, then tell yourself the truth: this ache is yearning, and yearning is what love does when someone is gone. "The LORD is close to the brokenhearted and saves those who are crushed in spirit." Psalm 34:18 (NIV). He doesn't wait for you to finish a stage before He comes close. Click the link in my bio to learn more about self-brain surgery for grief.
1
3
6
648